{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:22:17Z","timestamp":1768879337653,"version":"3.49.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.retram.2020.05.004","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T04:42:44Z","timestamp":1590813764000},"page":"93-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A review of potential treatments to date in COVID-19 patients according to the stage of the disease"],"prefix":"10.1016","volume":"68","author":[{"given":"Tamim","family":"Alsuliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lugien","family":"Alasadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banan","family":"Alkharat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alrstom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2020.05.004_bib0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013Infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.retram.2020.05.004_bib0010","series-title":"Coronavirus disease 2019 (COVID-19) Situation Report \u2013 92","author":"WHO","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2004973","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1","author":"Van Doremalen","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0020","first-page":"1","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection\u2014a review of immune changes in patients with viral pneumonia","author":"Lin","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.retram.2020.05.004_bib0025","article-title":"Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment","author":"Hassan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.retram.2020.05.004_bib0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","article-title":"How will country-based mitigation measures influence the course of the COVID-19 epidemic?","volume":"395","author":"Anderson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.retram.2020.05.004_bib0035","article-title":"COVID-19 treatment: a review of early and emerging options","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.retram.2020.05.004_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.retram.2020.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.retram.2020.05.004_bib0050","series-title":"Coronavirus disease 2019 (COVID-19) Situation Report \u2013 46","author":"WHO","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0055","series-title":"CDC COVID-19 response team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) \u2014 united States, February 12\u2013march 16","first-page":"2020","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0060","series-title":"Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Interim guidance","author":"WHO","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0065","article-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.retram.2020.05.004_bib0070","series-title":"Neutrophil-to-Lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage","author":"Liu","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0075","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3786","article-title":"Detection of SARS-CoV-2 in different types of clinical specimens","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.retram.2020.05.004_bib0080","article-title":"Development and clinical application of a rapid IgM\u2010IgG combined antibody test for SARS\u2010CoV\u20102 infection diagnosis","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.retram.2020.05.004_bib0085","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2020200642","article-title":"Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases","author":"Ai","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.retram.2020.05.004_bib0090","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2020200343","article-title":"Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing","author":"Xie","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.retram.2020.05.004_bib0100","series-title":"Global surveillance for COVID-19 caused by human infection with COVID-19 virus Interim guidance","author":"WHO","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0105","series-title":"Updated guidance on evaluating and testing persons for coronavirus disease 2019 (COVID-19) 2020","author":"CDC","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0110","series-title":"Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment","author":"China National Health Commission","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30165-X","article-title":"Understanding pathways to death in patients with COVID-19","author":"Vincent","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.retram.2020.05.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools","author":"Fu","year":"2020","journal-title":"Virol Sin"},{"key":"10.1016\/j.retram.2020.05.004_bib0130","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.retram.2020.05.004_bib0135","series-title":"Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients","author":"FDA","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0140","series-title":"COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes","author":"EMA","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.retram.2020.05.004_bib0150","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0155","article-title":"Hydroxychloroquine in Covid-19: Does the end justify the means?","author":"Yakoub-Agha","year":"2020","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","author":"Ko","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.retram.2020.05.004_bib0165","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0170","series-title":"First 12 patients with coronavirus disease 2019 (COVID-19) in the United States","author":"Kujawski","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0175","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0180","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir\u2013Ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0185","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.retram.2020.05.004_bib0190","series-title":"A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19","author":"Belhadi","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","author":"Deng","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.retram.2020.05.004_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30262-0","article-title":"Baricitinib for COVID-19: a suitable treatment?","author":"Favalli","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.retram.2020.05.004_bib0205","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013Angiotensin\u2013Aldosterone system inhibitors in patients with Covid-19","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.retram.2020.05.004_bib0215","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","author":"Diaz","year":"2020","journal-title":"J Travel Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0220","series-title":"The use of adjuvant therapy in preventing progression to severe pneumonia in patients with coronavirus disease 2019: a multicenter data analysis","author":"Feng","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0225","series-title":"BC centre for disease control. Unproven therapies for COVID-19","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0230","series-title":"The impact of camostat mesilate on COVID-19 infection - full text view - ClinicalTrials.gOv","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0235","series-title":"Combination therapy with camostat mesilate + hydroxychloroquine for COVID-19 - full text view - ClinicalTrials.gOv","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0240","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2020200463","article-title":"Chest CT findings in coronavirus Disease-19 (COVID-19): relationship to duration of infection","author":"Bernheim","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.retram.2020.05.004_bib0245","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19\u2014a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.retram.2020.05.004_bib0250","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.retram.2020.05.004_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104362","article-title":"Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past","volume":"127","author":"Giannis","year":"2020","journal-title":"J Clin Virol"},{"key":"10.1016\/j.retram.2020.05.004_bib0260","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","author":"Thachil","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.retram.2020.05.004_bib0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.retram.2020.05.004_bib0270","series-title":"Chloroquine as a potential treatment and prevention measure for the 2019 novel coronavirus: a review","author":"Kearney","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0275","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.retram.2020.05.004_bib0280","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.retram.2020.05.004_bib0285","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-020-0674-9","article-title":"Insights from nanomedicine into chloroquine efficacy against COVID-19","author":"Hu","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.retram.2020.05.004_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.retram.2020.05.004_bib0295","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"CHEN","year":"2020","journal-title":"J Zhejiang Univ"},{"key":"10.1016\/j.retram.2020.05.004_bib0300","series-title":"Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial","author":"Tang","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0305","author":"Borba","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0310","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.retram.2020.05.004_bib0315","series-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.retram.2020.05.004_bib0325","series-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study","author":"Gautret","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0330","article-title":"COVID\u201019: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society\u2010led International Task Force","author":"Wilson","year":"2020","journal-title":"Am Thorac Soc"},{"key":"10.1016\/j.retram.2020.05.004_bib0335","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0340","series-title":"Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Revista Panamericana De Salud P\u00fablica"},{"key":"10.1016\/j.retram.2020.05.004_bib0350","series-title":"Solidarity\u201d clinical trial for COVID-19 treatments","author":"WHO","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0355","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.retram.2020.05.004_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.retram.2020.05.004_bib0365","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"Rossignol","year":"2016","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.retram.2020.05.004_bib0370","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.retram.2020.05.004_bib0375","article-title":"Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients","author":"Zhou","year":"2020","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.retram.2020.05.004_bib0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.retram.2020.05.004_bib0385","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa102","article-title":"High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.retram.2020.05.004_bib0390","series-title":"Short-term moderate-dose corticosteroid plus ImmunoglobuliK.-Y. Effectively reverses COVID-19 patients who have failed low-dose therapy","author":"Zhou","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0395","first-page":"1173","article-title":"Pentaglobin in steroid-resistant severe acute respiratory syndrome","volume":"8","author":"Ho","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.retram.2020.05.004_bib0400","series-title":"Research C for BE and. Revised information for investigational COVID-19 convalescent plasma","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0405","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.retram.2020.05.004_bib0410","series-title":"Effective treatment of severe COVID-19 patients with tocilizumab","author":"Xu","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0415","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.retram.2020.05.004_bib0420","series-title":"Leronlimab used in seven patients with severe COVID-19 demonstrated promise with two intubated patients in ICU, removed from ICU and extubated with reduced pulmonary inflammation","author":"CytoDyn Inc","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0425","series-title":"RACCOMANDAZIONI DI ETICA CLINICA PER L\u2019AMMISSIONE A TRATTAMENTI INTENSIVI E PER LA LORO SOSPENSIONE, IN CONDIZIONI ECCEZIONALI DI SQUILIBRIO TRA NECESSIT\u00c0 E RISORSE DISPONIBILI","author":"di Anestesia","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0430","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis"},{"key":"10.1016\/j.retram.2020.05.004_bib0435","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/jcm9030682","article-title":"MSC based therapies\u2014new perspectives for the injured lung","volume":"9","author":"Behnke","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0440","series-title":"Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells","author":"Liang","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0445","first-page":"E71","article-title":"Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use","volume":"23","author":"Atluri","year":"2020","journal-title":"Pain Phys."},{"key":"10.1016\/j.retram.2020.05.004_bib0450","series-title":"Investigational new drug (IND) application. FDA","author":"Center for Drug Evaluation and Research","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0455","series-title":"Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support","author":"Gritti","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0460","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","article-title":"Potential interventions for novel coronavirus in China: a systematic review","volume":"92","author":"Zhang","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.retram.2020.05.004_bib0465","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.retram.2020.05.004_bib0470","series-title":"NIH clinical trial of investigational vaccine for COVID-19 begins","author":"NIH","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.retram.2020.05.004_bib0480","series-title":"DRAFT landscape of COVID-19 candidate vaccines","author":"WHO","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0485","series-title":"Critical preparedness, readiness and response actions for COVID-19 Interim guidance","author":"WHO","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0490","series-title":"Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study","author":"Miller","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0495","series-title":"BCG vaccination may be protective against Covid-19","author":"Hegarty","year":"2020"},{"key":"10.1016\/j.retram.2020.05.004_bib0500","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.00332","article-title":"BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny","volume":"11","author":"Angelidou","year":"2020","journal-title":"Front Microbiol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318620300374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318620300374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:38:41Z","timestamp":1762821521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318620300374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S2452318620300374"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2020.05.004","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of potential treatments to date in COVID-19 patients according to the stage of the disease","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2020.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}